Dyne Therapeutics (DYN) Stock Price, News & Analysis

Company Overview

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells. This strategy aims to address the challenges of systemic delivery and off‐target effects that have limited prior antisense and gene therapy efforts in neuromuscular disorders. By optimizing both the ligand and the cargo, Dyne seeks to achieve sustained target engagement in affected tissues while minimizing exposure elsewhere.

Headquartered in Cambridge, Massachusetts, Dyne Therapeutics operates research and development facilities in the United States and collaborates with partners across Europe and Asia to support global clinical development. The company completed its initial public offering on the Nasdaq market in early 2021, enabling the expansion of its pipeline and investment in manufacturing capabilities for future late‐stage programs.

Dyne’s leadership team brings together executives with extensive experience in biotechnology, pharmaceutical development and clinical operations. The company is governed by a board of directors and scientific advisory members who have led successful drug development programs across multiple therapeutic areas. Dyne continues to engage with patient communities, regulatory agencies and academic institutions to advance its mission of delivering next‐generation therapies for people living with devastating neuromuscular diseases.

Key Stats

• Today's Range: $26.02 to $26.87
• 50-Day Range: $18.07 to $26.78
• 52-Week Range: $11.92 to $27.31
• Volume: 1.18 million shs
• Average Volume: 1.98 million shs
• Market Capitalization: $4.87 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $34.42
• Consensus Rating: Moderate Buy

Dyne Therapeutics Stock Analysis - MarketRank™

Dyne Therapeutics scored higher than 68% of companies evaluated by MarketBeat, and ranked 242nd out of 915 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Dyne Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on 2 strong buy ratings, 10 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Dyne Therapeutics has a consensus price target of $34.42, representing about 31.9% upside from its current price of $26.10.

Amount of Analyst Coverage

Dyne Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Dyne Therapeutics are expected to grow in the coming year, from ($3.47) to ($3.25) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Dyne Therapeutics is -7.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Dyne Therapeutics is -7.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Dyne Therapeutics has a P/B Ratio of 3.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.99% of the float of Dyne Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Dyne Therapeutics has a short interest ratio ("days to cover") of 7.18.

Change versus previous month

Short interest in Dyne Therapeutics has recently increased by 2.23%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Dyne Therapeutics does not currently pay a dividend.

Dividend Growth

Dyne Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.28

News Sentiment

Dyne Therapeutics has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 23 news articles for Dyne Therapeutics this week, compared to 6 articles on an average week.

Search Interest

Only 3 people have searched for DYN on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

MarketBeat Follows

1 people have added Dyne Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Dyne Therapeutics insiders have sold 87,136.71% more of their company's stock than they have bought. Specifically, they have bought $114,000.00 in company stock and sold $99,449,852.00 in company stock.

Percentage Held by Insiders

9.46% of the stock of Dyne Therapeutics is held by insiders.

Percentage Held by Institutions

96.68% of the stock of Dyne Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/30/2026
• Today: 8/24/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:DYN
• Previous Symbol: NYSE:DYN
• CIK: 1818794
• Web: www.dyne-tx.com
• Phone: 781-786-8230
• Fax: 781-786-8866
• Employees: 100
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Dyne Therapeutics: $34.42
• High Price Target: $50.00
• Low Price Target: $16.00
• Potential Upside/Downside: +31.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.87
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.33)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$446.21 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -64.30%
• Return on Assets: -50.33%

Debt

• Debt-to-Equity Ratio: 0.28
• Current Ratio: 12.02
• Quick Ratio: 12.02

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.81 per share
• Price / Book: 3.83

Miscellaneous

• Outstanding Shares: 186,750,000
• Free Float: 169,080,000
• Market Cap: $4.87 billion
• Optionable: Optionable
• Beta: 1.07